An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
暂无分享,去创建一个
[1] A. Alhatem,et al. Dupilumab-associated mycosis fungoides: a cross-sectional study. , 2023, Archives of dermatological research.
[2] A. Elsensohn,et al. Cutaneous T‐cell lymphoma following dupilumab use: a systematic review , 2022, International journal of dermatology.
[3] M. Maurer,et al. Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study , 2022, Frontiers in Immunology.
[4] A. Bursztejn,et al. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.
[5] H. Kim,et al. TRPM8 agonist (cryosim‐1) gel for scalp itch: a randomised, vehicle‐controlled clinical trial , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] P. Myles,et al. Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine , 2022, Anaesthesia.
[7] M. Metz,et al. Characterization of the effects on pruritus by novel treatments for atopic dermatitis , 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[8] Wook-Joo Lee,et al. Cutaneous Neuroimmune Interactions of TSLP and TRPV4 Play Pivotal Roles in Dry Skin-Induced Pruritus , 2021, Frontiers in Immunology.
[9] S. Mishra,et al. Role of TRP ion channels in pruritus , 2021, Neuroscience Letters.
[10] Reid H. J. Olsen,et al. Structure, function and pharmacology of human itch GPCRs , 2021, Nature.
[11] S. Ständer,et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[12] E. Carstens,et al. Glucosylsphingosine evokes pruritus via activation of 5‐HT2A receptor and TRPV4 in sensory neurons , 2021, British journal of pharmacology.
[13] Langchong He,et al. p-Phenylenediamine induces immediate contact allergy and non-histaminergic itch via MRGPRX2. , 2021, Chemico-biological interactions.
[14] V. Julia,et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. , 2021, The Journal of allergy and clinical immunology.
[15] E. Deeks. Difelikefalin: First Approval , 2021, Drugs.
[16] M. Gut,et al. Interleukin-4 and interleukin-13 induce different metabolic profiles in microglia and macrophages that relate with divergent outcomes after spinal cord injury , 2021, Theranostics.
[17] J. Schroeder,et al. IL-3 in the development and function of basophils. , 2021, Seminars in immunology.
[18] M. Gajewska,et al. Primary cutaneous indolent B-cell lymphomas – a retrospective multicenter analysis and a review of literature , 2021, Acta oncologica.
[19] H. Stark,et al. TRPV1 and TRPA1 Channels Are Both Involved Downstream of Histamine-Induced Itch , 2021, Biomolecules.
[20] A. Evers,et al. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[21] Ana Helena Santos,et al. IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch , 2021, Advances in hematology.
[22] G. Yosipovitch,et al. A protracted, postherpetic neuralgic ulcer treated with risperidone and intranasal butorphanol , 2021, JAAD case reports.
[23] Yong Chen,et al. Emerging Role of Transient Receptor Potential Vanilloid 4 (TRPV4) Ion Channel in Acute and Chronic Itch , 2021, International journal of molecular sciences.
[24] B. Chung,et al. Activation of Transient Receptor Potential Vanilloid-3 Channels in Keratinocytes Induces Pruritus in Humans , 2021, Acta dermato-venereologica.
[25] O. Sokumbi,et al. Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates , 2021, The American Journal of dermatopathology.
[26] Yuan Zhou,et al. Cimifugin relieves pruritus in psoriasis by inhibiting TRPV4. , 2021, Cell calcium.
[27] R. Willemze,et al. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants , 2021, Biochemistry and biophysics reports.
[28] Jennifer Y. Zhang,et al. Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine , 2021, Gastroenterology.
[29] F. Murray-Brown. Naltrexone for cholestatic itch: a systematic review , 2021, BMJ Supportive & Palliative Care.
[30] R. Dummer,et al. Cutaneous T‐cell Lymphoma , 2021, The Peripheral T‐Cell Lymphomas.
[31] M. M. Limberg,et al. Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions , 2021, Frontiers in Medicine.
[32] Masanari Sekine,et al. Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride , 2021, Scientific Reports.
[33] R. Ji,et al. Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition. , 2020, Brain : a journal of neurology.
[34] K. Russomanno,et al. Acceleration of cutaneous T-cell lymphoma following dupilumab administration , 2020, JAAD case reports.
[35] M. Polymeropoulos,et al. Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[36] J. Silverberg,et al. Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis. , 2020, Dermatitis : contact, atopic, occupational, drug.
[37] B. Chung,et al. A randomized, vehicle controlled clinical trial of a synthetic TRPM8 agonist (Cryosim-1) gel for itch. , 2020, Journal of the American Academy of Dermatology.
[38] H. Kim,et al. Itching Caused by TRPV3 (Transient Receptor Potential Vanilloid-3) Activator Application to Skin of Burn Patients , 2020, Medicina.
[39] N. Bragazzi,et al. Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data , 2020, The Journal of dermatological treatment.
[40] C. Schlapbach,et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[41] B. Elewski,et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* , 2020, The British journal of dermatology.
[42] K. Peris,et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* , 2020, The British journal of dermatology.
[43] Ellen J. Kim,et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. , 2020, Cutis.
[44] Hong Liu,et al. Mast cells and thymic stromal lymphopoietin (TSLP) expression positively correlates with pruritus intensity in dermatitis herpetiformis , 2020, European Journal of Dermatology.
[45] T. Buhl,et al. Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis , 2020, Frontiers in Immunology.
[46] G. Foulke,et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. , 2020, Cutis.
[47] S. Kimura,et al. Dupilumab therapy in Sézary syndrome misdiagnosed as atopic dermatitis: A case report , 2020, The Journal of dermatology.
[48] S. Kwatra,et al. Intranasal Butorphanol Rescue Therapy for the Treatment of Intractable Pruritus: A Case Series from the Johns Hopkins Itch Clinic. , 2020, Journal of the American Academy of Dermatology.
[49] T. Zuberbier,et al. Effective treatment with mepolizumab in a patient with refractory Wells syndrome , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[50] Mark J. Miller,et al. A basophil-neuronal axis promotes itch , 2020, Cell.
[51] J. Sanches,et al. Progression of mycosis fungoides after treatment with dupilumab: A case report , 2020, Dermatologic therapy.
[52] M. Bagot,et al. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas , 2020, Acta dermato-venereologica.
[53] G. Yosipovitch,et al. Use of Butorphanol as Treatment for Cholestatic Itch , 2020, Digestive Diseases and Sciences.
[54] P. Kwon,et al. Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. , 2020, Journal of the American Academy of Dermatology.
[55] T. Hashimoto,et al. Mechanisms of itch in stasis dermatitis: Significant role of IL-31 from macrophages. , 2020, The Journal of investigative dermatology.
[56] J. Silverberg,et al. Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients. , 2020, Journal of the American Academy of Dermatology.
[57] J. Silverberg,et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. , 2020, Journal of the American Academy of Dermatology.
[58] A. Armstrong,et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis , 2020, JAMA dermatology.
[59] M. Lebwohl,et al. Serlopitant for Psoriatic Pruritus: a Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial. , 2020, Journal of the American Academy of Dermatology.
[60] F. Menzaghi,et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients , 2020, Kidney international reports.
[61] Zhou-Feng Chen,et al. PAR2 mediates itch via TRPV3 signaling in keratinocytes. , 2020, The Journal of investigative dermatology.
[62] S. Schwartz,et al. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions , 2020, Clinical Reviews in Allergy & Immunology.
[63] T. Billiar,et al. TSLP protects against liver I/R injury via activation of the PI3K/Akt pathway. , 2019, JCI insight.
[64] S. Ziegler,et al. TSLP: from allergy to cancer , 2019, Nature Immunology.
[65] M. Nedergaard,et al. Astrocytes in chronic pain and itch , 2019, Nature Reviews Neuroscience.
[66] K. Bergmann,et al. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[67] N. Osada,et al. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[68] Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. , 2019, Blood.
[69] P. Fallon,et al. IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. , 2019, The Journal of investigative dermatology.
[70] P. Kwon,et al. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus , 2019, Expert opinion on investigational drugs.
[71] T. Chiba,et al. Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis. , 2019, Acta dermato-venereologica.
[72] M. Kishibe. Physiological and pathological roles of kallikrein-related peptidases in the epidermis. , 2019, Journal of dermatological science.
[73] A. Reich,et al. NK-1 Receptor Antagonists and Pruritus: Review of Current Literature , 2019, Dermatology and Therapy.
[74] T. Hashimoto,et al. Pruritus in ordinary scabies: IL‐31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin , 2019, Allergy.
[75] D. Elston,et al. The uses of naltrexone in dermatologic conditions. , 2019, Journal of the American Academy of Dermatology.
[76] W. Kempf,et al. Cutaneous lymphomas—An update 2019 , 2019, Hematological oncology.
[77] S. Snyder,et al. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus , 2019, Proceedings of the National Academy of Sciences.
[78] M. Malcangio,et al. Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour , 2019, Neurobiology of pain.
[79] T. Luger,et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo‐controlled trial , 2019, Journal of the American Academy of Dermatology.
[80] Xinzhong Dong,et al. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. , 2019, Immunity.
[81] K. Kridin,et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.
[82] V. Nielsen,et al. The kallikrein-like activity of Heloderma venom is inhibited by carbon monoxide , 2019, Journal of Thrombosis and Thrombolysis.
[83] J. Gerss,et al. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). , 2019, Acta dermato-venereologica.
[84] E. Simpson,et al. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial , 2019, Journal of the American Academy of Dermatology.
[85] G. Dranoff,et al. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. , 2019, Immunity.
[86] A. Murakami,et al. The proteolytic effect of mast cell tryptase to eotaxin-1/CCL11·eotaxin-2/CCL24 and eotaxin-3/CCL26 produced by conjunctival fibroblasts , 2019, Japanese Journal of Ophthalmology.
[87] L. Ferrer,et al. PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models. , 2019, The Journal of investigative dermatology.
[88] V. Gaponenko,et al. Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness , 2019, The Journal of allergy and clinical immunology.
[89] E. Lerner,et al. Targeting PAR2 with Pepducins. , 2019, The Journal of investigative dermatology.
[90] N. Mesinkovska,et al. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review , 2019, JAMA dermatology.
[91] B. Kim,et al. Efficacy and safety of PAC‐14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild‐to‐moderate atopic dermatitis: a phase IIb randomized trial† , 2019, The British journal of dermatology.
[92] S. Tishchenko,et al. Interleukin-17: Functional and Structural Features, Application as a Therapeutic Target , 2019, Biochemistry (Moscow).
[93] G. Porebski,et al. Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions , 2018, Front. Immunol..
[94] M. Duvic,et al. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma , 2018, American Journal of Clinical Dermatology.
[95] M. Soligo,et al. Nerve Growth Factor: Early Studies and Recent Clinical Trials , 2018, Current neuropharmacology.
[96] M. Hollenberg,et al. Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation , 2018, Scientific Reports.
[97] T. Hashimoto,et al. Modulation of Itch by Localized Skin Warming and Cooling. , 2018, Acta dermato-venereologica.
[98] W. Zieglgänsberger. Substance P and pain chronicity , 2018, Cell and Tissue Research.
[99] N. Brown,et al. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial , 2018, JAMA dermatology.
[100] M. Furue,et al. Nemolizumab in patients with moderate‐to‐severe atopic dermatitis: Randomized, phase II, long‐term extension study , 2018, The Journal of allergy and clinical immunology.
[101] Guoqiang Shangguan,et al. Biological Properties and the Role of IL-25 in Disease Pathogenesis , 2018, Journal of immunology research.
[102] L. Misery,et al. Real‐life study of anti‐itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[103] S. Mott,et al. Health‐related quality of life in patients with cutaneous T‐cell lymphoma? , 2018, International journal of dermatology.
[104] Yong Ho Kim,et al. miRNA-711 Binds and Activates TRPA1 Extracellularly to Evoke Acute and Chronic Pruritus , 2018, Neuron.
[105] A. Sobolevsky,et al. Structure and Gating Mechanism of the Transient Receptor Potential Channel TRPV3 , 2018, Nature Structural & Molecular Biology.
[106] M. Duvic,et al. Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T‐cell lymphoma , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[107] I. Junttila. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes , 2018, Front. Immunol..
[108] H. Tey,et al. The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. , 2018, The Journal of investigative dermatology.
[109] Y. Asano,et al. Interleukin‐25 is involved in cutaneous T‐cell lymphoma progression by establishing a T helper 2‐dominant microenvironment , 2018, The British journal of dermatology.
[110] J. R. de Sousa,et al. Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update , 2018, Front. Immunol..
[111] Xinzhong Dong,et al. Peripheral and Central Mechanisms of Itch , 2018, Neuron.
[112] Matthew B. Kerby,et al. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo‐controlled phase 2 clinical trial , 2018, Journal of the American Academy of Dermatology.
[113] S. Nakae,et al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity , 2018, Scientific Reports.
[114] P. Ortiz-Romero,et al. Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas , 2018, The British journal of dermatology.
[115] V. Lisowski,et al. Inhibitors of kallikrein‐related peptidases: An overview , 2018, Medicinal research reviews.
[116] Rupali Gupta,et al. Regulation of Pain and Itch by TRP Channels , 2018, Neuroscience Bulletin.
[117] Y. Asano,et al. Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome , 2018, The Journal of dermatology.
[118] V. Mathur,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus , 2017, American Journal of Nephrology.
[119] D. McKemy,et al. Cooling Relief of Acute and Chronic Itch Requires TRPM8 Channels and Neurons. , 2017, The Journal of investigative dermatology.
[120] M. Kolacz,et al. Perioperative analgesia after intrathecal fentanyl and morphine or morphine alone for cesarean section , 2017, Medicine.
[121] Yuetsu Tanaka,et al. The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis , 2017, Virology Journal.
[122] E. Healy,et al. Persistent kallikrein 5 activation induces atopic dermatitis‐like skin architecture independent of PAR2 activity , 2017, The Journal of allergy and clinical immunology.
[123] Hongzhen Hu,et al. Sensory TRP channels contribute differentially to skin inflammation and persistent itch , 2017, Nature Communications.
[124] S. Kwatra,et al. Aprepitant for the Treatment of Chronic Refractory Pruritus , 2017, BioMed research international.
[125] T. Muramatsu,et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[126] Y. Kuraishi,et al. Involvement of Leukotriene B4 Released from Keratinocytes in Itch-associated Response to Intradermal Interleukin-31 in Mice. , 2017, Acta dermato-venereologica.
[127] Hongzhen Hu,et al. Transient receptor potential vanilloid 4–expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch , 2017, The Journal of allergy and clinical immunology.
[128] T. Nagano,et al. Aprepitant for refractory nivolumab-induced pruritus. , 2017, Lung cancer.
[129] S. Ständer,et al. Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double‐blind, controlled, pilot study in dry skin , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[130] P. Jagodziński,et al. Opioid Receptors in Psoriatic Skin: Relationship with Itch. , 2017, Acta dermato-venereologica.
[131] Ling Meng,et al. Tryptase inhibitors: a patent review , 2017, Expert opinion on therapeutic patents.
[132] Jonathan R. Brestoff,et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.
[133] B. Eiz-Vesper,et al. Human basophils are a source of ‐ and are differentially activated by ‐ IL‐31 , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[134] T. Kupper,et al. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature , 2017, BMC Cancer.
[135] C. Pincelli. p75 Neurotrophin Receptor in the Skin: Beyond Its Neurotrophic Function , 2017, Front. Med..
[136] J. Breed,et al. Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. , 2017, Journal of molecular biology.
[137] T. Zuberbier,et al. Skin provocation tests may help to diagnose atopic dermatitis , 2016, Allergy.
[138] A. Huber,et al. An emerging role for eotaxins in neurodegenerative disease. , 2016, Clinical immunology.
[139] D. Fairlie,et al. Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease‐activated receptor‐2 , 2016, British journal of pharmacology.
[140] S. Hirakawa,et al. Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice. , 2016, Journal of dermatological science.
[141] P. Kruzliak,et al. Role of substance P in the cardiovascular system , 2016, Neuropeptides.
[142] M. Maurer,et al. Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[143] Wei Cheng,et al. Facilitation of TRPV4 by TRPV1 is required for itch transmission in some sensory neuron populations , 2016, Science Signaling.
[144] R. Dana,et al. Neuropeptide substance P and the immune response , 2016, Cellular and Molecular Life Sciences.
[145] Jungsoo Lee,et al. Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus , 2016, Annals of dermatology.
[146] J. Guitart,et al. Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. , 2016, Acta dermato-venereologica.
[147] E. Kontny,et al. Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features , 2016, International journal of dermatology.
[148] M. Tani,et al. Eotaxin-3 (CCL26) Expression in Human Pancreatic Myofibroblasts , 2016, Pancreas.
[149] M. Nagamine,et al. Involvement of TRPV4 in serotonin-evoked scratching , 2015, The Journal of investigative dermatology.
[150] H. Hermanns. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. , 2015, Cytokine & growth factor reviews.
[151] Y. Kuraishi,et al. Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis , 2015, Experimental dermatology.
[152] Y. Liu,et al. Tryptase and protease-activated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. , 2015, International immunopharmacology.
[153] M. Furue,et al. Mutual upregulation of endothelin‐1 and IL‐25 in atopic dermatitis , 2015, Allergy.
[154] E. Magen,et al. Plasma endothelin-1 levels during exacerbation of atopic dermatitis. , 2015, Allergy and asthma proceedings.
[155] B. Boyce,et al. Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. , 2015, Acta dermato-venereologica.
[156] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[157] H. Watarai,et al. Interleukin-17B Antagonizes Interleukin-25-Mediated Mucosal Inflammation. , 2015, Immunity.
[158] A. Hawi,et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus , 2015, BMC Nephrology.
[159] A. Khosravi,et al. Role of IL-25 in Immunity. , 2015, Journal of clinical and diagnostic research : JCDR.
[160] M. Sokołowska-Wojdyło,et al. Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. , 2015, Acta dermato-venereologica.
[161] T. Kupper,et al. CCR4 + T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16 , 2015, Leukemia & lymphoma.
[162] A. Luster,et al. The chemokine system in innate immunity. , 2015, Cold Spring Harbor perspectives in biology.
[163] M. Maurer,et al. Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. , 2014, The Journal of investigative dermatology.
[164] N. Upton,et al. Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviour , 2014, Experimental dermatology.
[165] Xinzhong Dong,et al. Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.
[166] N. Alenina,et al. Mas and Its Related G Protein–Coupled Receptors, Mrgprs , 2014, Pharmacological Reviews.
[167] M. Casanova,et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report , 2014, Journal of Medical Case Reports.
[168] R. Dummer,et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[169] T. Buhl,et al. Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus. , 2014, The Journal of clinical investigation.
[170] Jie Tan,et al. Continous Epidural Butorphanol Decreases the Incidence of Intrathecal Morphine-Related Pruritus After Cesarean Section: A Randomized, Double-Blinded, Placebo-Controlled Trial , 2014, Cell Biochemistry and Biophysics.
[171] Alain Hovnanian,et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome , 2014, The Journal of experimental medicine.
[172] D. Polley,et al. Biased signalling and proteinase‐activated receptors (PARs): targeting inflammatory disease , 2014, British journal of pharmacology.
[173] S. Horwitz,et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. , 2014, Journal of the American Academy of Dermatology.
[174] G. Yosipovitch,et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. , 2013, The Journal of investigative dermatology.
[175] W. Busse,et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.
[176] E. Carstens,et al. Neural processing of itch , 2013, Neuroscience.
[177] W. Silny,et al. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus , 2013, Postepy dermatologii i alergologii.
[178] S. Jordt,et al. TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[179] M. Kido,et al. CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury , 2013, Cell Death and Disease.
[180] Christina S Gamba,et al. The use of aprepitant in brachioradial pruritus. , 2013, JAMA dermatology.
[181] S. Bevan,et al. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B4‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[182] M. Maurer,et al. Effective control of recalcitrant pruritus by bevacizumab: a possible role for vascular endothelial growth factor in chronic itch? , 2013, Acta dermato-venereologica.
[183] Y. Tada,et al. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. , 2013, Acta dermato-venereologica.
[184] E. Olsen,et al. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. , 2012, Journal of the American Academy of Dermatology.
[185] B. Vincenzi,et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. , 2012, The Lancet. Oncology.
[186] Jung Hyun Han,et al. Topical TRPM8 agonist (icilin) relieved vulva pruritus originating from lichen sclerosus et atrophicus. , 2012, Acta dermato-venereologica.
[187] J. Wallengren. Topical aprepitant in clinical and experimental pruritus. , 2012, Archives of dermatology.
[188] M. Duvic,et al. Prevalence and severity of pruritus in cutaneous T cell lymphoma , 2012, International journal of dermatology.
[189] K. Yasui,et al. TRPV3 as a therapeutic target for itch. , 2012, The Journal of investigative dermatology.
[190] Q. H. Tran,et al. Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study , 2012, Journal of Anesthesia.
[191] Y. Tada,et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. , 2012, Acta dermato-venereologica.
[192] Kyung‐Min Lim,et al. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases , 2012, Archives of pharmacal research.
[193] Ruoyu Li,et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. , 2012, American journal of human genetics.
[194] S. E. Ross. Pain and itch: insights into the neural circuits of aversive somatosensation in health and disease , 2011, Current Opinion in Neurobiology.
[195] I. Dekio,et al. Content of Vascular Endothelial Growth Factor in Stratum Corneum Well Correlates to Local Severity of Acute Inflammation in Patients with Atopic Dermatitis , 2011, International Archives of Allergy and Immunology.
[196] M. Sugaya,et al. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. , 2011, Journal of dermatological science.
[197] E. Theodorsson,et al. Expression of tachykinins and their receptors in plaque psoriasis with pruritus , 2011, The British journal of dermatology.
[198] J. Utikal,et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T‐cell lymphoma , 2011, The British journal of dermatology.
[199] S. Ryser,et al. PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin , 2011, Nature communications.
[200] T. Luger,et al. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. , 2010, Journal of the American Academy of Dermatology.
[201] Shinichi Sato,et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. , 2010, The Journal of investigative dermatology.
[202] T. Luger,et al. Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy , 2010, PloS one.
[203] T. Luger,et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. , 2010, Journal of dermatological science.
[204] P. Brousset,et al. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome. , 2010, The Journal of investigative dermatology.
[205] T. Muramatsu,et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[206] H. Watarai,et al. Regulation of IL-9 expression by IL-25 signaling , 2010, Nature Immunology.
[207] R. Geha,et al. Thymic stromal lymphopoietin , 2010, Annals of the New York Academy of Sciences.
[208] David J. Anderson,et al. Sensory Neuron-Specific GPCR Mrgprs Are Itch Receptors Mediating Chloroquine-Induced Pruritus , 2009, Cell.
[209] K. Takatsu,et al. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. , 2009, International immunology.
[210] G. Joshi,et al. Role of intravenous naloxone in severe pruritus of acute cholestasis , 2009, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
[211] M. Sugaya,et al. Increased serum thymic stromal lymphopoietin levels in patients with cutaneous T cell lymphoma , 2009, Clinical and experimental dermatology.
[212] S. Devesa,et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.
[213] R. Watanabe,et al. Increased CCL1 levels in the sera and blister fluid of patients with bullous pemphigoid. , 2009, Journal of dermatological science.
[214] P. Carmeliet,et al. Role and therapeutic potential of VEGF in the nervous system. , 2009, Physiological reviews.
[215] G. Baliva,et al. Quality of life and psychological distress in patients with cutaneous lymphoma. , 2009 .
[216] Minoru Suzuki,et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. , 2009, The Journal of investigative dermatology.
[217] T. I. Lund Nilsen,et al. Incidence of primary cutaneous T‐cell lymphoma in Norway , 2009, The British journal of dermatology.
[218] K. Takatsu,et al. IL-5 and eosinophilia. , 2008, Current opinion in immunology.
[219] Manfred Schmitt,et al. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7 , 2008, Biological chemistry.
[220] E. Diamandis,et al. Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.
[221] H. Stammer,et al. Treatment of pruritus with topically applied opiate receptor antagonist. , 2007, Journal of the American Academy of Dermatology.
[222] E. Diamandis,et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients , 2007, Experimental dermatology.
[223] S.E. Chang,et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus , 2007, The British journal of dermatology.
[224] D. McQueen,et al. Endothelin‐1 activates ETA receptors to cause reflex scratching in BALB/c mice , 2007, British journal of pharmacology.
[225] S. Gan,et al. Significant impact of cutaneous T‐cell lymphoma on patients' quality of life , 2006, Cancer.
[226] T. Kawakami,et al. Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. , 2006, Journal of dermatological science.
[227] G. Caughey. Tryptase genetics and anaphylaxis. , 2006, The Journal of allergy and clinical immunology.
[228] Y. Maezawa,et al. Interleukin 25 in Allergic Airway Inflammation , 2006, International Archives of Allergy and Immunology.
[229] O. Johansson,et al. Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study , 2006, Archives of Dermatological Research.
[230] G. Yosipovitch,et al. Butorphanol for treatment of intractable pruritus. , 2006, Journal of the American Academy of Dermatology.
[231] E. Morita,et al. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis , 2006, Archives of Dermatological Research.
[232] A. Skoff,et al. Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors , 2006, Experimental Neurology.
[233] H. Nojima,et al. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. , 2006, European journal of pharmacology.
[234] Y. Ueno,et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. , 2005, Journal of the American Society of Nephrology : JASN.
[235] A. Keegan,et al. Interleukin-4 (IL-4) Pathway , 2005, Science's STKE.
[236] J. Holden,et al. The endogenous opioid system and clinical pain management. , 2005, AACN clinical issues.
[237] Nicola Pimpinelli,et al. WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.
[238] M. Dugas,et al. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[239] H. Zentgraf,et al. CCL1-CCR8 Interactions: An Axis Mediating the Recruitment of T Cells and Langerhans-Type Dendritic Cells to Sites of Atopic Skin Inflammation1 , 2005, The Journal of Immunology.
[240] Craig Montell,et al. The TRP Superfamily of Cation Channels , 2005, Science's STKE.
[241] T. Luger,et al. Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon , 2004, Der Hautarzt.
[242] Bart Landuyt,et al. Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.
[243] P. Kam,et al. Mast cell tryptase: a review of its physiology and clinical significance , 2004, Anaesthesia.
[244] Lisa M. Ebert,et al. A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells , 2004, Journal of Experimental Medicine.
[245] N. Bunnett,et al. Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.
[246] M. Morohashi,et al. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch‐associated cutaneous factors , 2003, The British journal of dermatology.
[247] E. Goldin,et al. Topical capsaicin—a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study , 2003, Gut.
[248] Thomas A. Luger,et al. Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin , 2003, The Journal of Neuroscience.
[249] E. Papadavid,et al. The relevance of peripheral blood T‐helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome , 2003, The British journal of dermatology.
[250] T. Makino,et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis , 2002 .
[251] D. Banville,et al. Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.
[252] O. Johansson,et al. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia , 2002, Archives of Dermatological Research.
[253] Luting Xu,et al. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. , 2001, The Journal of investigative dermatology.
[254] M. Steinhoff,et al. Proteinase‐activated receptor‐2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase , 1999, Experimental dermatology.
[255] J. Sullivan,et al. Naltrexone: A case report of pruritus from an antipruritic , 1997, The Australasian journal of dermatology.
[256] E. Crosby,et al. Treatment of intrathecal morphine-induced pruritus following Caesarean section , 1997 .
[257] M. Hollenberg,et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[258] D. Alling,et al. Effects of Naloxone Infusions in Patients with the Pruritus of Cholestasis: A Double-Blind, Randomized, Controlled Trial , 1995, Annals of Internal Medicine.
[259] G. Krueger,et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. , 1993, Journal of the American Academy of Dermatology.
[260] T. Ebendal. Function and evolution in the NGF family and its receptors , 1992, Journal of neuroscience research.
[261] A. Rook,et al. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. , 1992, The Journal of investigative dermatology.
[262] A. Levine,et al. Disulfide assignments in recombinant mouse and human interleukin 4. , 1991, Biochemistry.
[263] S. Seidenari,et al. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study , 1990, The British journal of dermatology.
[264] E. Monroe. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. , 1989, Journal of the American Academy of Dermatology.
[265] H. S. Earl,et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.
[266] J. Silverberg,et al. Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.
[267] M. Tominaga,et al. The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin. , 2017, Allergology international : official journal of the Japanese Society of Allergology.
[268] C. Woolf,et al. Substance P activates Mas‐related G protein–coupled receptors to induce itch , 2017, The Journal of allergy and clinical immunology.
[269] Yoon Seok Yang,et al. Increased expression of three types of transient receptor potential channels (TRPA1, TRPV4 and TRPV3) in burn scars with post-burn pruritus. , 2015, Acta dermato-venereologica.
[270] C. Curiel-Lewandrowski,et al. Absence of full-length neurokinin-1 receptor protein expression by cutaneous T cells: implications for substance P-mediated signaling in mycosis fungoides. , 2015, Acta dermato-venereologica.
[271] S. Whittaker,et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. , 2013, Journal of pain and symptom management.
[272] T. Pusl,et al. Pathogenesis and Treatment of Pruritus in Cholestasis , 2012, Drugs.
[273] T. Torres,et al. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. , 2012, Journal of the American Academy of Dermatology.
[274] L. Misery,et al. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. , 2010, Acta dermato-venereologica.
[275] Jung-Bum Lee,et al. Involvement of Tryptase and Proteinase-Activated Receptor-2 in Spontaneous Itch-Associated Response in Mice With Atopy-like Dermatitis. , 2009, Journal of pharmacological sciences.
[276] M. Steinhoff,et al. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. , 2008, The Journal of investigative dermatology.
[277] C. Montell,et al. TRP channels. , 2007, Annual review of biochemistry.
[278] M. Minami,et al. Molecular pharmacology of the opioid receptors. , 1995, Pharmacology & therapeutics.
[279] S. Ferreira,et al. Endothelin‐1 Participation in Overt and Inflammatory Pain , 1989, Journal of cardiovascular pharmacology.